Would Ugandan University Students Use CAB-LA for HIV Prevention?

In Uganda, HIV prevention is a major concern, especially among young females. A study at a public university aimed to uncover what might influence female students' willingness to use a long-acting HIV prevention drug called Cabotegravir (CAB-LA). This drug is injected every two months, making it a convenient option for those with high HIV risk behaviors. The researchers wanted to know if these students would consider CAB-LA as a preventive measure. They focused on factors that could sway their decision. For instance, how much they trust the drug and if they understand its benefits. One key finding was that students who had more knowledge about HIV were more likely to consider using CAB-LA. This makes sense because understanding the disease can make preventive measures more appealing.

Another interesting point was that students' willingness also depended on how comfortable they felt about getting injections. Some might prefer pills over injections, even if the latter is more convenient. The study also found that students who had supportive friends or family were more open to the idea of CAB-LA. This highlights the importance of social support in health decisions. Overall, the study showed that while many students were willing to use CAB-LA, there were still barriers to overcome. These include lack of knowledge about the drug, discomfort with injections, and the need for more social support.

Actions